VERAXA Biotech files first BiTAC patent applications, portfolio tops 50 Jul 29, 2026 07:03AM
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates Jul 29, 2026 07:00AM
VERAXA Biotech advances VXA-222 bispecific ADC program with OmniAb Jul 27, 2026 07:00AM
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb Jul 27, 2026 07:00AM
Veraxa Biotech shareholders approve all EGM resolutions with 99.94% vote Jul 24, 2026 04:06PM


Jul 24, 2026 04:05PM VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
Jul 23, 2026 07:02AM Veraxa Biotech names Christoph Erkel as chief scientific officer
Jul 23, 2026 07:00AM VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
Jul 20, 2026 07:03AM Veraxa Biotech receives regulatory guidance on BiTAC-TCE cancer therapy
Jul 20, 2026 07:00AM VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
Jul 13, 2026 07:01AM VERAXA Biotech partners with Ardigen on AI drug discovery for cancer
Jul 13, 2026 07:00AM VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
Jul 10, 2026 04:05PM VERAXA Biotech names Carl von Halem as interim CFO
Jul 10, 2026 04:05PM VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
Jul 6, 2026 07:01AM VERAXA Biotech targets first BiTAC candidate IND-ready by 2028
Jul 6, 2026 07:00AM VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
Jul 2, 2026 07:00AM Veraxa Biotech starts cell line development with ATUM for cancer therapy
Jul 2, 2026 07:00AM VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program
Jun 24, 2026 07:00AM VERAXA Biotech expands lab space at Heidelberg R&D site
Jun 24, 2026 07:00AM VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development
Jun 24, 2026 07:00AM VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development
Jun 18, 2026 07:02AM VERAXA Biotech reports in vitro data for its BiTAC-ADC platform
Jun 18, 2026 07:00AM VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
Jun 10, 2026 04:15PM VERAXA Biotech completes merger, begins NASDAQ trading
Jun 10, 2026 04:15PM VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026